CRCAM BRIE PIC2-CCI (CRBP2.PA) Fundamental Analysis & Valuation

EPA:CRBP2 • FR0010483768

27.458 EUR
-0.14 (-0.51%)
Last: Mar 4, 2026, 12:43 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

This CRBP2.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

Taking everything into account, CRBP2 scores 2 out of 10 in our fundamental rating. CRBP2 was compared to 106 industry peers in the Banks industry. Both the profitability and financial health of CRBP2 have multiple concerns. CRBP2 does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

2

1. CRBP2.PA Profitability Analysis

1.1 Basic Checks

  • CRBP2 had positive earnings in the past year.
  • In the past year CRBP2 has reported a negative cash flow from operations.
  • CRBP2 had positive earnings in each of the past 5 years.
  • In multiple years CRBP2 reported negative operating cash flow during the last 5 years.
CRBP2.PA Yearly Net Income VS EBIT VS OCF VS FCFCRBP2.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B -1B

1.2 Ratios

  • CRBP2's Return On Assets of 0.53% is on the low side compared to the rest of the industry. CRBP2 is outperformed by 64.15% of its industry peers.
  • CRBP2's Return On Equity of 3.86% is on the low side compared to the rest of the industry. CRBP2 is outperformed by 76.42% of its industry peers.
Industry RankSector Rank
ROA 0.53%
ROE 3.86%
ROIC N/A
ROA(3y)0.47%
ROA(5y)0.46%
ROE(3y)3.92%
ROE(5y)3.92%
ROIC(3y)N/A
ROIC(5y)N/A
CRBP2.PA Yearly ROA, ROE, ROICCRBP2.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 1 2 3 4 5

1.3 Margins

  • CRBP2 has a better Profit Margin (26.10%) than 66.98% of its industry peers.
  • In the last couple of years the Profit Margin of CRBP2 has declined.
  • CRBP2 does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) 26.1%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-6.32%
PM growth 5Y-2.49%
GM growth 3YN/A
GM growth 5YN/A
CRBP2.PA Yearly Profit, Operating, Gross MarginsCRBP2.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20 25

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. CRBP2.PA Health Analysis

2.1 Basic Checks

  • CRBP2 does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, CRBP2 has less shares outstanding
  • CRBP2 has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, CRBP2 has an improved debt to assets ratio.
CRBP2.PA Yearly Shares OutstandingCRBP2.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CRBP2.PA Yearly Total Debt VS Total AssetsCRBP2.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B

2.2 Solvency

  • CRBP2 has a Debt/Equity ratio of 0.20. This is a healthy value indicating a solid balance between debt and equity.
  • CRBP2's Debt to Equity ratio of 0.20 is amongst the best of the industry. CRBP2 outperforms 85.85% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACC6.26%
CRBP2.PA Yearly LT Debt VS Equity VS FCFCRBP2.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B

2.3 Liquidity

Industry RankSector Rank
Current Ratio N/A
Quick Ratio N/A
CRBP2.PA Yearly Current Assets VS Current LiabilitesCRBP2.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. CRBP2.PA Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 7.77% over the past year.
  • The Earnings Per Share has been growing slightly by 1.97% on average over the past years.
  • The Revenue has decreased by -1.48% in the past year.
  • CRBP2 shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.72% yearly.
EPS 1Y (TTM)7.77%
EPS 3Y-3.01%
EPS 5Y1.97%
EPS Q2Q%14.23%
Revenue 1Y (TTM)-1.48%
Revenue growth 3Y3.81%
Revenue growth 5Y4.72%
Sales Q2Q%-1.45%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CRBP2.PA Yearly Revenue VS EstimatesCRBP2.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

Find the best growth stocksShow best growing peers

2

4. CRBP2.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 6.83, the valuation of CRBP2 can be described as very cheap.
  • CRBP2's Price/Earnings ratio is rather cheap when compared to the industry. CRBP2 is cheaper than 92.45% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 26.83, CRBP2 is valued rather cheaply.
Industry RankSector Rank
PE 6.83
Fwd PE N/A
CRBP2.PA Price Earnings VS Forward Price EarningsCRBP2.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRBP2.PA Per share dataCRBP2.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 100 200 300

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)3.46
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

5

5. CRBP2.PA Dividend Analysis

5.1 Amount

  • CRBP2 has a Yearly Dividend Yield of 3.96%.
  • CRBP2's Dividend Yield is comparable with the industry average which is at 4.33.
  • Compared to an average S&P500 Dividend Yield of 1.82, CRBP2 pays a better dividend.
Industry RankSector Rank
Dividend Yield 3.96%

5.2 History

  • The dividend of CRBP2 has a limited annual growth rate of 1.28%.
Dividend Growth(5Y)1.28%
Div Incr Years3
Div Non Decr Years3
CRBP2.PA Yearly Dividends per shareCRBP2.PA Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 0.2 0.4 0.6 0.8 1

5.3 Sustainability

  • CRBP2's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DPN/A
EPS Next 2YN/A
EPS Next 3YN/A
CRBP2.PA Yearly Income VS Free CF VS DividendCRBP2.PA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B -1B

More info and screens

Find the best dividend stocksShow peers with best dividend

CRBP2.PA Fundamentals: All Metrics, Ratios and Statistics

CRCAM BRIE PIC2-CCI

EPA:CRBP2 (3/4/2026, 12:43:10 PM)

27.458

-0.14 (-0.51%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupBanks
GICS IndustryBanks
Earnings (Last)01-29
Earnings (Next)04-21
Inst Owners3.5%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap423.13M
Revenue(TTM)837.21M
Net Income(TTM)218.51M
Analysts83.64
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 3.96%
Yearly Dividend0.71
Dividend Growth(5Y)1.28%
DPN/A
Div Incr Years3
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 6.83
Fwd PE N/A
P/S 0.51
P/FCF N/A
P/OCF N/A
P/B 0.07
P/tB 0.07
EV/EBITDA N/A
EPS(TTM)4.02
EY14.64%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-28.78
FCFYN/A
OCF(TTM)-27.99
OCFYN/A
SpS54.33
BVpS367.54
TBVpS367.53
PEG (NY)N/A
PEG (5Y)3.46
Graham Number182.33
Profitability
Industry RankSector Rank
ROA 0.53%
ROE 3.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 26.1%
GM N/A
FCFM N/A
ROA(3y)0.47%
ROA(5y)0.46%
ROE(3y)3.92%
ROE(5y)3.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-6.32%
PM growth 5Y-2.49%
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 59.41%
Cap/Sales 1.46%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio N/A
Quick Ratio N/A
Altman-Z N/A
F-Score5
WACC6.26%
ROIC/WACCN/A
Cap/Depr(3y)66.63%
Cap/Depr(5y)90.91%
Cap/Sales(3y)1.62%
Cap/Sales(5y)2.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.77%
EPS 3Y-3.01%
EPS 5Y1.97%
EPS Q2Q%14.23%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-1.48%
Revenue growth 3Y3.81%
Revenue growth 5Y4.72%
Sales Q2Q%-1.45%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y81.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y82.29%
OCF growth 3YN/A
OCF growth 5YN/A

CRCAM BRIE PIC2-CCI / CRBP2.PA FAQ

What is the fundamental rating for CRBP2 stock?

ChartMill assigns a fundamental rating of 2 / 10 to CRBP2.PA.


What is the valuation status of CRCAM BRIE PIC2-CCI (CRBP2.PA) stock?

ChartMill assigns a valuation rating of 2 / 10 to CRCAM BRIE PIC2-CCI (CRBP2.PA). This can be considered as Overvalued.


What is the profitability of CRBP2 stock?

CRCAM BRIE PIC2-CCI (CRBP2.PA) has a profitability rating of 2 / 10.


Can you provide the financial health for CRBP2 stock?

The financial health rating of CRCAM BRIE PIC2-CCI (CRBP2.PA) is 2 / 10.